R.-D. Hofheinz , F. Herrle , T. Dechow , L.F. von Weikersthal , M. Welslau , S. Lettmaier , C. Burkart , S. Kubicka , L. Kochen , K. Merx , K. Krause , M. Ebert , C. Rödel , E. Fokas , M. Ghadimi , C. Reissfelder , T. Gaiser
{"title":"“mFOLFOX6与mFOLFOX6 +阿伯西普作为mri定义的t3直肠癌的新辅助治疗:德国直肠癌研究组(CAO/ARO/AIO 0214)和ABCSG (R-06)的随机ii期试验”的更正","authors":"R.-D. Hofheinz , F. Herrle , T. Dechow , L.F. von Weikersthal , M. Welslau , S. Lettmaier , C. Burkart , S. Kubicka , L. Kochen , K. Merx , K. Krause , M. Ebert , C. Rödel , E. Fokas , M. Ghadimi , C. Reissfelder , T. Gaiser","doi":"10.1016/j.esmoop.2024.104095","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 2","pages":"Article 104095"},"PeriodicalIF":8.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”\",\"authors\":\"R.-D. Hofheinz , F. Herrle , T. Dechow , L.F. von Weikersthal , M. Welslau , S. Lettmaier , C. Burkart , S. Kubicka , L. Kochen , K. Merx , K. Krause , M. Ebert , C. Rödel , E. Fokas , M. Ghadimi , C. Reissfelder , T. Gaiser\",\"doi\":\"10.1016/j.esmoop.2024.104095\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11877,\"journal\":{\"name\":\"ESMO Open\",\"volume\":\"10 2\",\"pages\":\"Article 104095\"},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2059702924018660\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Open","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2059702924018660","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”
期刊介绍:
ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research.
ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO.
Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.